| Cardiff Oncology (CRDF) Upgraded to Buy: Here's What You Should Know |
Cardiff Oncology (CRDF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-05-14 17:05:37 |
Czytaj oryginał (ang.) |
| Cardiff Oncology: Buying The First-Line Onvansertib Strategy |
Cardiff Oncology's onvansertib shows promise as a first-in-class PLK1 inhibitor for first-line RAS-mutated metastatic colorectal cancer, potentially redefining standard-of-care and achieving blockbuster status. Onvansertib's synergy with bevacizumab and promising clinical data support its pivot to first-line treatment, with potential peak global sales of $1.2B to $2B annually. Despite strong prospects, CRDF faces risks including clinical/regulatory hurdles, market competition, and financial challenges, necessitating potential dilutive funding for Phase III trials and commercialization. |
seekingalpha.com |
2025-05-14 13:05:10 |
Czytaj oryginał (ang.) |
| Cardiff Oncology (CRDF) Reports Q1 Loss, Lags Revenue Estimates |
Cardiff Oncology (CRDF) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.22 per share a year ago. |
zacks.com |
2025-05-08 22:25:36 |
Czytaj oryginał (ang.) |
| Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update |
- Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer (“mCRC”) - - Expanded intellectual property portfolio with second patent covering treatment of all bev-naïve patients, including RAS-mutated and RAS wild-type mCRC, across all lines of therapy - - Cash and investments of $79.9 million as of March 31, 2025, projected runway into Q1 2027 - SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. “Our lead program for onvansertib has remained on track in 2025 with the successful completion of enrollment in our trial in first-line RAS-mutated mCRC, underscoring our deep commitment to serving a patient population that has seen no therapeutic advancements in decades,” said Mark Erlander, Chief Executive Officer of Cardiff Oncology. |
globenewswire.com |
2025-05-08 20:05:00 |
Czytaj oryginał (ang.) |
| Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon |
Cardiff Oncology's onvansertib shows promising early results in improving response rates for RAS-mutated colorectal cancer, with a critical data update expected by mid-2025. Financially, CRDF has sufficient funds to operate until early 2027 but will face funding challenges by 2026, potentially impacting stock value. The success of onvansertib in first-line metastatic colorectal cancer is crucial, with high upside potential but significant risk if upcoming data disappoints. |
seekingalpha.com |
2025-05-02 07:35:02 |
Czytaj oryginał (ang.) |
| Cardiff Oncology (CRDF) Expected to Beat Earnings Estimates: Should You Buy? |
Cardiff Oncology (CRDF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-24 15:09:24 |
Czytaj oryginał (ang.) |
| Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients |
The claims cover combination treatment of onvansertib + bev for all bev-naïve patients including RAS-mutated and RAS wild type mCRC across all lines of therapy through 2043 The claims cover combination treatment of onvansertib + bev for all bev-naïve patients including RAS-mutated and RAS wild type mCRC across all lines of therapy through 2043 |
globenewswire.com |
2025-04-23 20:05:00 |
Czytaj oryginał (ang.) |
| Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that on April 14, 2025, non-qualified stock option awards to purchase an aggregate of 35,040 shares of its common stock were granted to one new employee. The stock options were granted as inducements material to the new employee becoming an employee of Cardiff Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-04-15 20:10:00 |
Czytaj oryginał (ang.) |
| Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer |
- Initial results from randomized Phase 2 CRDF-004 trial in RAS-mut mCRC were released in December 2024 - - Additional clinical data from CRDF-004 trial expected in 1H 2025 - SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced completion of patient enrollment in the ongoing Phase 2 CRDF-004 trial evaluating onvansertib in combination with standard of care (SoC) for the treatment of first-line RAS-mutated metastatic colorectal cancer (mCRC). “The successful completion of enrollment in our first-line trial for patients with RAS mutant mCRC represents an important milestone in our mission to develop new treatments for a population who have not seen meaningful treatment advancements for decades. |
globenewswire.com |
2025-04-15 20:05:00 |
Czytaj oryginał (ang.) |
| All You Need to Know About Cardiff Oncology (CRDF) Rating Upgrade to Buy |
Cardiff Oncology (CRDF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-03-04 15:05:26 |
Czytaj oryginał (ang.) |
| Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript |
Cardiff Oncology, Inc. (NASDAQ:CRDF ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Kiki Patel - Investor Relations, Gilmartin Group Mark Erlander - Chief Executive Officer Jamie Levine - Chief Financial Officer Conference Call Participants Joe Catanzaro - Piper Sandler Andy Hsieh - William Blair Robert Burns - H.C. Wainwright Albert Lowe - Craig-Hallum Operator Welcome to the Cardiff Oncology Fourth Quarter 2024 Financial Results and Business Update Conference Call. |
seekingalpha.com |
2025-02-27 23:10:37 |
Czytaj oryginał (ang.) |
| Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates |
Cardiff Oncology (CRDF) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.21 per share a year ago. |
zacks.com |
2025-02-27 21:15:28 |
Czytaj oryginał (ang.) |
| Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update |
- Robust initial efficacy signal with onvansertib + chemo/bev in ongoing first-line RAS-mut metastatic colorectal cancer (“mCRC”) clinical trial (CRDF-004) - |
globenewswire.com |
2025-02-27 18:05:00 |
Czytaj oryginał (ang.) |
| Cardiff Oncology to Present at Upcoming Investor Conferences |
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present at two upcoming investor conferences. Details of the presentations can be found below. |
globenewswire.com |
2025-02-24 18:05:00 |
Czytaj oryginał (ang.) |
| Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update |
- Management will hold a conference call on Thursday, February 27 at 4:30 p.m. ET/1:30 p.m. PT - - Management will hold a conference call on Thursday, February 27 at 4:30 p.m. ET/1:30 p.m. PT - |
globenewswire.com |
2025-02-20 18:05:00 |
Czytaj oryginał (ang.) |
| Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib |
Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC, with a strong therapeutic profile and potential for high returns if approved. Onvansertib's Phase II results indicate superior efficacy in first-line treatment, supporting Cardiff's financial stability and long-term investment potential. The competitive landscape includes therapies like LUMAKRAS and KRAZATI, but Onvansertib's mutation-agnostic approach offers a unique advantage. |
seekingalpha.com |
2025-02-18 11:19:01 |
Czytaj oryginał (ang.) |
| Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone + |
The 'Undercovered' Dozen series highlights lesser-covered stocks, offering fresh investment ideas and sparking community discussions on their potential. Ubiquiti Inc. shows promise with operational improvements, Ready Capital Corporation faces liquidity risks, and TORM plc is crucial despite energy sector volatility. Esperion Therapeutics' breakout and Cardiff Oncology's promising trial data present compelling buy opportunities, while Advantest Corporation's high valuation suggests caution. |
seekingalpha.com |
2024-12-14 11:00:00 |
Czytaj oryginał (ang.) |
| Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning |
Cardiff Oncology's phase 2 trial of onvansertib in mCRC shows promising preliminary data, with improved response rates in a dose-dependent manner. Onvansertib appears well tolerated and effective when combined with standard chemotherapy and bevacizumab, but patient numbers remain low, necessitating further validation. Financially, CRDF's equity raise extends their cash runway, supporting the continued development and reducing immediate financial risk. |
seekingalpha.com |
2024-12-12 07:38:41 |
Czytaj oryginał (ang.) |
| CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study |
Cardiff Oncology stock rallies as initial data from a phase II study of onvansertib shows superior efficacy over SOC chemotherapy in colorectal cancer patients. |
zacks.com |
2024-12-11 13:06:16 |
Czytaj oryginał (ang.) |
| Cardiff Oncology: Beats Standard Of Care In First Line Metastatic Colorectal Cancer |
Cardiff Oncology's Phase 2 trial data for Onvansertib in metastatic colorectal cancer shows dose-related outperformance of standard care, with a combined ORR of 57% versus 33% in the control arm. The company plans to discuss with the FDA to potentially make the CRDF-004 trial a registrational trial, aiming for accelerated approval based on ORR. Cardiff's recent $40 million oversubscribed direct offering strengthens its financial position, ensuring over two years of operational funding. |
seekingalpha.com |
2024-12-10 19:05:28 |
Czytaj oryginał (ang.) |
| Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering |
SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF) (“Cardiff Oncology” or the “Company”), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced the pricing of an underwritten offering of 15,384,619 shares of its common stock at an offering price of $2.60 per share, before deducting underwriting discounts and commissions. All of the shares of common stock are being offered by the Company. The financing included participation from new mutual fund and healthcare dedicated investors, along with support from existing investors. |
globenewswire.com |
2024-12-10 09:20:00 |
Czytaj oryginał (ang.) |
| Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial |
- Initial results from randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care in RAS-mut mCRC demonstrated 64% ORR in the 30mg onvansertib dose arm versus 33% ORR in the control arm - |
globenewswire.com |
2024-12-10 08:00:00 |
Czytaj oryginał (ang.) |
| Cardiff Oncology (CRDF) Reports Q3 Loss, Tops Revenue Estimates |
Cardiff Oncology (CRDF) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.22 per share a year ago. |
zacks.com |
2024-11-07 21:10:53 |
Czytaj oryginał (ang.) |
| Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC |
- Findings underscore that the combination of onvansertib with FOLFIRI and bevacizumab demonstrates clinical activity and is well tolerated in second-line KRAS-mutant mCRC - |
globenewswire.com |
2024-10-30 18:30:00 |
Czytaj oryginał (ang.) |
| Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market |
Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated metastatic colorectal cancer, potentially opening a massive market with an estimated $567 million to $3.78 billion in annual US sales. Onvansertib has demonstrated superior efficacy and safety over historical controls and competitors, particularly in bevacizumab-naïve patients, with impressive objective response rates and progression-free survival. Positive data from the ongoing CRDF-004 trial could lead to significant upside for Cardiff, attracting potential partnerships or acquisition interest from big pharma, including Pfizer. |
seekingalpha.com |
2024-10-04 17:10:38 |
Czytaj oryginał (ang.) |
| Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point |
Cardiff Oncology, Inc. results from the phase 2 CRDF-004 study, using onvansertib + Folfiri + bevacizumab for the treatment of patients with RAS-mutant mCRC, expected in the 2nd half of 2024. The global colorectal cancer market is expected to reach $30.09 billion by 2033; It said that about 50% of mCRC patients harbor the RAS mutation. A new phase 2 investigator-sponsored study, using onvansertib + Nalirifox for the treatment of 1st-line PDAC patients, will be deployed soon. |
seekingalpha.com |
2024-08-12 18:57:19 |
Czytaj oryginał (ang.) |
| Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript |
Cardiff Oncology, Inc. (NASDAQ:CRDF ) Q2 2024 Results Conference Call August 8, 2024 4:30 PM ET Company Participants Kiki Patel - Investor Relations, Gilmartin Group Mark Erlander - Chief Executive Officer Jamie Levine - Chief Financial Officer Conference Call Participants Andy Hsieh - William Blair Marc Frahm - TD Cowen Operator Welcome to the Cardiff Oncology Second Quarter 2024 Financial Results and Business Update Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. |
seekingalpha.com |
2024-08-10 15:18:07 |
Czytaj oryginał (ang.) |
| Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates |
Cardiff Oncology (CRDF) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.25 per share a year ago. |
zacks.com |
2024-08-08 23:01:14 |
Czytaj oryginał (ang.) |
| Cardiff Oncology to Present at the Jefferies Healthcare Conference |
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a company presentation and 1x1 investor meetings at the Jefferies Healthcare Conference, which is taking place at the Marriott Marquis in New York from June 5-6, 2024. |
globenewswire.com |
2024-05-29 20:05:00 |
Czytaj oryginał (ang.) |
| Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data |
Cardiff Oncology's Onvansertib is a first-in-class oral PLK1 inhibitor that targets difficult-to-treat cancers such as mCRC, mPDAC, SCLC, and TNBC. Onvansertib's promising early data suggest that it overcomes treatment resistance, improves response rates, and extends progression-free survival. Ongoing Phase 2 trials for Onvansertib in various cancers include collaborations with Pfizer and other prestigious institutions. |
seekingalpha.com |
2024-05-22 03:22:53 |
Czytaj oryginał (ang.) |
| Cardiff Oncology to Present at Upcoming Investor Conferences in May |
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present at two upcoming investor conferences in May 2024. |
globenewswire.com |
2024-05-13 20:05:00 |
Czytaj oryginał (ang.) |
| The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028 |
Finding good investment opportunities in the constantly changing stock market is similar to uncovering hidden treasures. Certain cheap stocks to buy are particularly noteworthy because they can yield significant gains. |
investorplace.com |
2024-05-07 10:00:00 |
Czytaj oryginał (ang.) |
| Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript |
Cardiff Oncology, Inc. (NASDAQ:CRDF ) Q1 2024 Results Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Kiki Patel - Investor Relations, Gilmartin Group Mark Erlander - Chief Executive Officer Jamie Levine - Chief Financial Officer Conference Call Participants Mark Frahm - TD Cowen Joseph Catanzaro - Piper Sandler Andy Hsieh - William Blair Operator Welcome to the Cardiff Oncology First Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-05-03 05:30:09 |
Czytaj oryginał (ang.) |
| Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates |
Cardiff Oncology (CRDF) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.25 per share a year ago. |
zacks.com |
2024-05-02 22:46:16 |
Czytaj oryginał (ang.) |
| Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update |
- In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients and support ongoing first-line RAS-mutated mCRC lead program - |
globenewswire.com |
2024-05-02 20:05:00 |
Czytaj oryginał (ang.) |
| Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update |
- Management will hold a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m. |
globenewswire.com |
2024-04-25 20:05:00 |
Czytaj oryginał (ang.) |